BioXcel Therapeutics, Inc. (BTAIQ) shareholders
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vimal Mehta Joint filing with BioXcel LLC (20.50%), BioXcel Holdings, Inc. (20.50%) | 8,830,622 | 23.50% | 13D (active) amendment | Jun 6, 2024 |
| Oaktree Capital Holdings, LLC Joint filing with Oaktree Capital Group Holdings GP, LLC (5.20%) | 2,724,075 | 5.20% | 13G (passive) | Nov 25, 2024 |
| Israel A. Englander Joint filing with Millennium Management LLC (8.40%), Millennium Group Management LLC (8.40%) and 1 more | 1,835,192 | 8.40% | 13G (passive) amendment | Dec 31, 2025 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.20%), Israel A. Englander (5.20%) and 1 more | 1,028,053 | 5.20% | 13G (passive) | Sep 29, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BTAIQ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Millennium Management LLC | 2,114,710 | 6.76% | $2.98M | +177,950 | 0.00% |
| Oaktree Capital Management LP | 1,380,248 | 4.41% | $1.95M | +1,139,060 | 0.03% |
| Vanguard Capital Management LLC | 919,545 | 2.94% | $1.30M | +712,206 | 0.00% |
| Oaktree Fund Advisors, LLC | 245,585 | 0.78% | $346.27K | +202,672 | 0.60% |
| Geode Capital Management, LLC | 242,251 | 0.77% | $341.91K | +12,083 | 0.00% |
| BlackRock, Inc. | 179,433 | 0.57% | $253.00K | +95,151 | 0.00% |
| UBS Group AG | 158,065 | 0.50% | $222.87K | +105,277 | 0.00% |
| Citadel Advisors LLC | 149,220 | 0.48% | $210.40K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 136,937 | 0.44% | $193.08K | +52,016 | 0.00% |
| State Street Corp | 92,118 | 0.29% | $129.89K | – | 0.00% |
| FMR LLC | 90,300 | 0.29% | $127.32K | – | 0.00% |
| &partners | 83,588 | 0.27% | $117.86K | +2,724 | 0.00% |
| Jones Financial Companies Lllp | 63,139 | 0.20% | $82.71K | −68,650 | 0.00% |
| Northern Trust Corp | 56,318 | 0.18% | $79.41K | +20,005 | 0.00% |
| HighTower Advisors, LLC | 41,000 | 0.13% | $57.81K | – | 0.00% |
| Quadrature Capital Ltd | 38,038 | 0.12% | $53.63K | New | 0.00% |
| Headlands Technologies LLC | 25,556 | 0.08% | $36.03K | New | 0.00% |
| StoneX Group Inc. | 20,684 | 0.07% | $29.16K | New | 0.00% |
| Beacon Pointe Advisors, LLC | 18,837 | 0.06% | $26.56K | −40 | 0.00% |
| Susquehanna International Group, Llp | 17,200 | 0.05% | $24.25K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 46 | 6M | 19.7% | 10 / 12 | 8 / 3 | 3M | 2M |
| Q1 2026 | 40 | 5M | 17.4% | 8 / 9 | 7 / 8 | 3M | 0M |
| Q4 2025 | 41 | 4M | 11.3% | 11 / 11 | 8 / 4 | 1M | 0M |
| Q3 2025 | 35 | 2M | 7.5% | 9 / 14 | 3 / 9 | 2M | 0M |
| Q2 2025 | 35 | 1M | 2.0% | 9 / 6 | 8 / 5 | 0M | 0M |
| Q1 2025 | 31 | 0M | 1.2% | 6 / 10 | 12 / 24 | 0M | 0M |
| Q4 2024 | 49 | 1M | 1.7% | 9 / 9 | 18 / 10 | 0M | 0M |
| Q3 2024 | 50 | 0M | 0.6% | 5 / 7 | 27 / 28 | 0M | 0M |
| Q2 2024 | 74 | 1M | 2.0% | 23 / 21 | 20 / 22 | 0M | 0M |
| Q1 2024 | 74 | 1M | 1.9% | 12 / 18 | 25 / 11 | 0M | 0M |
| Q4 2023 | 73 | 1M | 1.9% | 12 / 24 | 26 / 25 | 0M | 0M |
| Q3 2023 | 86 | 1M | 2.0% | 19 / 21 | 34 / 21 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
11 funds held BTAIQ in Q2 2026, 78% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BTAIQ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 679,570 | 2.17% | $958.19K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 207,339 | 0.66% | $292.35K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 105,892 | 0.34% | $123.89K | 0.00% | May 31, 2026 |
| Select Biotechnology Portfolio | 90,300 | 0.29% | $105.65K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 89,205 | 0.28% | $125.78K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 34,237 | 0.11% | $40.06K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 29,546 | 0.09% | $34.57K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 10,872 | 0.03% | $12.72K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 5,946 | 0.02% | $8.38K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 651 | 0.00% | $918 | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -9,455 | -0.03% | -$13.33K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vimal Mehta | CEO and President, Director | 550,285 | 1.76% | Jun 17, 2026 |
| Richard I. Steinhart | Chief Financial Officer | 26,335 | 0.08% | Jun 17, 2026 |
| Javier Rodriguez | See Remarks | 26,838 | 0.09% | Jun 17, 2026 |
| Frank Yocca | Chief Scientific Officer | 26,210 | 0.08% | Jun 17, 2026 |
| Susan E. Atkins | Director | – | – | Aug 14, 2026 |
| Michal Votruba | Director | – | – | Jan 12, 2026 |
| David J. Mack | Director | 20,317 | 0.06% | Jan 12, 2026 |
| Sandeep Laumas | Director | – | – | Jan 12, 2026 |
| Rajiv Patni | Director | – | – | Jan 12, 2026 |
| Peter Mueller | Director | 299,795 | 0.96% | Jan 12, 2026 |
| Michael Patrick Miller | Director | – | – | Jan 12, 2026 |
| June Bray | Director | – | – | Jan 12, 2026 |
| Matthew T. Wiley | – | 19,011 | 0.06% | Apr 1, 2025 |
| Vincent O'Neill | – | 19,957 | 0.06% | Apr 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Vimal Mehta CEO and President, Director | Jun 15, 2026 | Option exercise | +219 | – | – | 69,817 |
| Frank Yocca Chief Scientific Officer | Jun 15, 2026 | Option exercise | +35 | – | – | 26,210 |
| Javier Rodriguez See Remarks | Jun 15, 2026 | Option exercise | +35 | – | – | 26,838 |
| Richard I. Steinhart Chief Financial Officer | Jun 15, 2026 | Option exercise | +35 | – | – | 26,335 |
| Javier Rodriguez See Remarks | May 20, 2026 | Sale(10b5-1 plan) | −6,560 | $1.08 | $7.08K | 26,803 |
| Frank Yocca Chief Scientific Officer | May 20, 2026 | Sale(10b5-1 plan) | −6,845 | $1.09 | $7.46K | 26,175 |
| Vimal Mehta CEO and President, Director | May 20, 2026 | Sale(10b5-1 plan) | −19,419 | $1.09 | $21.17K | 69,598 |
| Richard I. Steinhart Chief Financial Officer | May 20, 2026 | Sale(10b5-1 plan) | −6,845 | $1.09 | $7.46K | 26,300 |
| Javier Rodriguez See Remarks | May 4, 2026 | Option exercise | +17,500 | – | – | 33,363 |
| Frank Yocca Chief Scientific Officer | May 4, 2026 | Option exercise | +17,500 | – | – | 33,020 |
| Vimal Mehta CEO and President, Director | May 4, 2026 | Option exercise | +49,758 | – | – | 89,017 |
| Richard I. Steinhart Chief Financial Officer | May 4, 2026 | Option exercise | +17,500 | – | – | 33,145 |
| Vimal Mehta CEO and President, Director | May 1, 2026 | Option exercise | +18,000 | – | – | 39,259 |
| Richard I. Steinhart Chief Financial Officer | May 1, 2026 | Option exercise | +9,000 | – | – | 15,645 |
| Frank Yocca Chief Scientific Officer | May 1, 2026 | Option exercise | +9,000 | – | – | 15,520 |
| Javier Rodriguez See Remarks | May 1, 2026 | Option exercise | +9,000 | – | – | 15,863 |
| Vimal Mehta CEO and President, Director | Mar 15, 2026 | Option exercise | +219 | – | – | 21,259 |
| Javier Rodriguez See Remarks | Mar 15, 2026 | Option exercise | +35 | – | – | 6,863 |
| Richard I. Steinhart Chief Financial Officer | Mar 15, 2026 | Option exercise | +35 | – | – | 6,645 |
| Frank Yocca Chief Scientific Officer | Mar 15, 2026 | Option exercise | +35 | – | – | 6,520 |
| Vimal Mehta CEO and President, Director | Mar 14, 2026 | Option exercise | +164 | – | – | 21,040 |
| Javier Rodriguez See Remarks | Mar 14, 2026 | Option exercise | +33 | – | – | 6,828 |
| Richard I. Steinhart Chief Financial Officer | Mar 14, 2026 | Option exercise | +33 | – | – | 6,610 |
| Frank Yocca Chief Scientific Officer | Mar 14, 2026 | Option exercise | +33 | – | – | 6,485 |
| Frank Yocca Chief Scientific Officer | Dec 15, 2025 | Option exercise | +35 | – | – | 6,452 |
| Vimal Mehta CEO and President, Director | Dec 15, 2025 | Option exercise | +219 | – | – | 20,876 |
| Javier Rodriguez See Remarks | Dec 15, 2025 | Option exercise | +35 | – | – | 6,795 |
| Richard I. Steinhart Chief Financial Officer | Dec 15, 2025 | Option exercise | +35 | – | – | 6,577 |
| Frank Yocca Chief Scientific Officer | Dec 14, 2025 | Option exercise | +33 | – | – | 6,417 |
| Vimal Mehta CEO and President, Director | Dec 14, 2025 | Option exercise | +164 | – | – | 20,657 |
| Javier Rodriguez See Remarks | Dec 14, 2025 | Option exercise | +33 | – | – | 6,760 |
| Richard I. Steinhart Chief Financial Officer | Dec 14, 2025 | Option exercise | +33 | – | – | 6,542 |
| David J. Mack Director | Oct 31, 2025 | Option exercise | +1,694 | – | – | 20,317 |
| David J. Mack Director | Sep 30, 2025 | Option exercise | +1,694 | – | – | 18,623 |
| Richard I. Steinhart Chief Financial Officer | Sep 15, 2025 | Option exercise | +35 | – | – | 6,509 |
| Frank Yocca Chief Scientific Officer | Sep 15, 2025 | Option exercise | +35 | – | – | 6,384 |
| Javier Rodriguez See Remarks | Sep 15, 2025 | Option exercise | +35 | – | – | 6,727 |
| Vimal Mehta CEO and President, Director | Sep 15, 2025 | Option exercise | +219 | – | – | 20,493 |
| Richard I. Steinhart Chief Financial Officer | Sep 14, 2025 | Option exercise | +33 | – | – | 6,474 |
| Frank Yocca Chief Scientific Officer | Sep 14, 2025 | Option exercise | +33 | – | – | 6,349 |
| Javier Rodriguez See Remarks | Sep 14, 2025 | Option exercise | +33 | – | – | 6,692 |
| Vimal Mehta CEO and President, Director | Sep 14, 2025 | Option exercise | +163 | – | – | 20,274 |
| David J. Mack Director | Aug 31, 2025 | Option exercise | +1,693 | – | – | 16,930 |
| David J. Mack Director | Jul 31, 2025 | Option exercise | +1,693 | – | – | 15,237 |
| Javier Rodriguez See Remarks | Jul 22, 2025 | Award | +4,375 | – | – | 6,034 |
| Javier Rodriguez See Remarks | Jul 22, 2025 | Option exercise | +625 | – | – | 6,659 |
| Richard I. Steinhart Chief Financial Officer | Jul 22, 2025 | Option exercise | +625 | – | – | 6,441 |
| Richard I. Steinhart Chief Financial Officer | Jul 22, 2025 | Award | +4,375 | – | – | 5,816 |
| Frank Yocca Chief Scientific Officer | Jul 22, 2025 | Award | +4,375 | – | – | 6,316 |
| Vimal Mehta CEO and President, Director | Jul 22, 2025 | Award | +15,625 | – | – | 20,111 |
| David J. Mack Director | Jun 30, 2025 | Option exercise | +1,693 | – | – | 13,544 |
| Vimal Mehta CEO and President, Director | Jun 15, 2025 | Option exercise | +219 | – | – | 4,486 |
| Richard I. Steinhart Chief Financial Officer | Jun 15, 2025 | Option exercise | +35 | – | – | 1,441 |
| Javier Rodriguez See Remarks | Jun 15, 2025 | Option exercise | +35 | – | – | 1,659 |
| Frank Yocca Chief Scientific Officer | Jun 15, 2025 | Option exercise | +35 | – | – | 1,941 |
| Vimal Mehta CEO and President, Director | Jun 14, 2025 | Option exercise | +163 | – | – | 4,267 |
| Richard I. Steinhart Chief Financial Officer | Jun 14, 2025 | Option exercise | +33 | – | – | 1,406 |
| Javier Rodriguez See Remarks | Jun 14, 2025 | Option exercise | +33 | – | – | 1,624 |
| Frank Yocca Chief Scientific Officer | Jun 14, 2025 | Option exercise | +33 | – | – | 1,906 |
| David J. Mack Director | May 31, 2025 | Option exercise | +1,693 | – | – | 11,851 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 2 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioXcel Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,927,474 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Vimal Mehta Officer | May 20, 2026 | 19,419 | $21.11K | May 20, 2026 | Vesting of restricted stock unit awards |
| Javier Rodriguez Officer | May 20, 2026 | 6,560 | $7.11K | May 20, 2026 | Vesting of restricted stock unit awards |
| Frank Yocca Officer | May 20, 2026 | 6,845 | $7.43K | May 20, 2026 | Vesting of restricted stock unit awards |
| Richard I. Steinhart Officer | May 20, 2026 | 6,845 | $7.43K | May 20, 2026 | Vesting of restricted stock unit awards |
| Javier Rodriguez Officer | Dec 16, 2024 | 430 | $153 | Dec 16, 2024 | Restricted Stock Units |
| Vincent O'Neill Officer | Dec 16, 2024 | 165 | $58 | Dec 16, 2024 | Restricted Stock Units |
| Frank Yocca Officer | Dec 16, 2024 | 430 | $152 | Dec 16, 2024 | Restricted Stock Units |
| Richard I. Steinhart Officer | Dec 16, 2024 | 438 | $154 | Dec 16, 2024 | Restricted Stock Units |
| Richard I. Steinhart Officer | Dec 16, 2024 | 430 | $154 | Dec 16, 2024 | Restricted Stock Units |
| Vimal Mehta Officer | Dec 16, 2024 | 2,298 | $793 | Dec 16, 2024 | Restricted Stock Units |
| Javier Rodriguez Officer | Oct 3, 2024 | 6,863 | $3.78K | Oct 3, 2024 | Performance Stock Units |
| Vincent O'Neill Officer | Oct 3, 2024 | 5,556 | $3.06K | Oct 3, 2024 | Performance Stock Units |
| Frank Yocca Officer | Oct 3, 2024 | 7,175 | $3.95K | Oct 3, 2024 | Performance Stock Units |
| Richard I. Steinhart Officer | Oct 3, 2024 | 7,175 | $3.95K | Oct 3, 2024 | Performance stock unit |
| Matthew T. Wiley Officer | Oct 3, 2024 | 6,272 | $3.45K | Oct 3, 2024 | Performance Stock Units |
See a number that looks wrong?